Metagenomic Next-Generation Sequencing Improves the Diagnosis Efficiency of Mixed Periprosthetic Joint Infections

Zibo Zhou1, Yanhua Song1, Yafang Yan1

  • 1Department of Clinical Laboratory, Zhengzhou Orthopaedics Hospital, Zhengzhou, Henan, 450000, People's Republic of China.

Abstract

Insights

Metagenomic next-generation sequencing (mNGS) offers higher sensitivity for diagnosing mixed periprosthetic joint infections (PJI), detecting more co-pathogens than traditional culture. This advanced technique aids in faster, targeted therapy for improved patient outcomes.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Genomics

Background:

  • Periprosthetic joint infections (PJI) pose significant challenges in orthopedic surgery.
  • Accurate diagnosis of mixed PJIs, involving multiple pathogens, is crucial for effective treatment.
  • Current diagnostic methods, like microbial culture, often have limitations in detecting all causative agents.

Purpose of the Study:

  • To evaluate the clinical utility of metagenomic next-generation sequencing (mNGS) for diagnosing mixed periprosthetic joint infections (PJI).
  • To compare the diagnostic performance of mNGS against traditional microbial culture in PJI cases.

Main Methods:

  • Retrospective analysis of patients with suspected PJI undergoing arthroplasty.
  • Comparison of results from microbial culture and mNGS analyses.
  • Statistical evaluation of sensitivity, specificity, and predictive values for both diagnostic methods.

Main Results:

  • mNGS demonstrated significantly higher sensitivity (79.55% vs 45.45%) and accuracy (80.70% vs 57.89%) compared to microbial culture.
  • For mixed PJIs, mNGS showed markedly improved sensitivity (72.23% vs 27.27%) in detecting co-pathogens.
  • While mNGS had lower specificity (84.62%) than culture (100%), it facilitated more comprehensive pathogen identification.

Conclusions:

  • mNGS is a valuable tool for the sensitive and rapid detection of co-pathogens in mixed PJI.
  • The integration of mNGS into clinical practice can accelerate targeted therapy and improve antimicrobial stewardship.
  • Further clinical validation is needed to optimize the use of mNGS, considering its specificity profile.